Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients

Journal of Infection

Volumn 71, Issue 1, 2015, Pages 28-36

  Polverino, Eva ^a   Cilloniz, Catia ^a   Menendez, Rosario ^b   Gabarrus, Albert ^a   Rosales Mayor, Edmundo ^a   Alcaraz, Victoria ^a   Terraneo, Silvia ^c   Puig de la Bella Casa, Jordi ^d   Mensa, Josep ^d   Ferrer, Miquel ^a   Torres, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c UNIVERSITY OF MILAN   (Italy)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Community acquired pneumonia; Etiology; Non cystic fibrosis bronchiectasis

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; CORTICOSTEROID; GLYCOPEPTIDE; INFLUENZA VACCINE; MACROLIDE; PNEUMOCOCCUS VACCINE; QUINOLONE DERIVATIVE;

AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; ENTEROBACTERIACEAE; FEMALE; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MIXED INFECTION; MONOTHERAPY; NON CYSTIC FIBROSIS BRONCHIECTASIS; NONHUMAN; OBSERVATIONAL STUDY; PATHOGENESIS; PREVALENCE; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RESPIRATORY VIRUS; STREPTOCOCCUS PNEUMONIAE; ADULT; BRONCHIECTASIS; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; MICROBIOLOGY; MIDDLE AGED; PNEUMONIA; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; BRONCHIECTASIS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PROSPECTIVE STUDIES;

EID: 84930540731     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.03.009     Document Type: Article

References (37)

1. Vendrell M., de Gracia J., Olveira C., Martínez M.A., Girón R., Máiz L., et al. Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery. Arch Bronconeumol 2008 Nov, 44(11):629-640.
2. Pasteur M.C., Bilton D., Hill A.T. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010 Jul, 65(Suppl. 1):i1-58.
3. Department of Health.NHLBI.UK, 2003-2004 Hospital episode statistics 2002-2003 2012.
4. Weycker D., Edelsberg J., Oster G., Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005, 12(4):205-209.
5. Twiss J., Metcalfe R., Edwards E., Byrnes C. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 2005 Jul, 90(7):737-740.
6. Nicotra M., River M., Dale A. Clinical, pathophysiologic and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995, 108:955-961.
7. King P.T., Holdsworth S.R., Freezer N.J., Villanueva E., Holmes P.W. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006 Dec, 100(12):2183-2189.
8. Habesoglu M.A., Ugurlu A.O., Eyuboglu F.O. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Ann Thorac Med 2011 Jul, 6(3):131-136.
9. Saynajakangas O., Keistinen T. A bronchiectatic patient's risk of pneumonia and prognosis. Cent Eur J Public Health 2009 Dec, 17(4):203-206.
10. Quinti I., Soresina A., Guerra A., Rondelli R., Spadaro G., Agostini C., et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011 Jun, 31(3):315-322.
11. King P.T., Holdsworth S.R., Freezer N.J., Villanueva E., Holmes P.W. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007 Aug, 101(8):1633-1638.
12. Angrill J., Agustí C., de Celis R., Rañó A., Gonzalez J., Solé T., et al. Bacterial colonization in patients with bronchiectasis: prevalence and comparison of diagnostic techniques 1999, p. A559. 159 ed.
13. Torres A., Barberán J., Falguera M., Menéndez R., Molina J., Olaechea P., et al. Multidisciplinary guidelines for the management of community-acquired pneumonia. Med Clin (Barc) 2013 Mar 2, 140(5):223.
14. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 Mar 1, 44(Suppl. 2):S27-S72.
15. Smyth A.R., Bell S.C., Bojcin S., Bryon M., Duff A., Flume P., et al. European Cystic Fibrosis Society Standards of Care: best practice guidelines. J Cyst Fibros 2014 May, 13(Suppl. 1):S23-S42.
16. Pasteur M.C., Helliwell S.M., Houghton S.J., Webb S.C., Foweraker J.E., Coulden R.A., et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000, 162:1277-1284.
17. Cillóniz C., Ewig S., Polverino E., Marcos M.A., Esquinas C., Gabarrús A., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011 Apr, 66(4):340-346.
18. Menendez R., Torres A., Aspa J., Capelastegui A., Prat C., Rodriguez de C.F. Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR). Arch Bronconeumol 2010 Oct, 46(10):543-558.
19. Roson B., Carratala J., Fernandez-Sabe N., Tubau F., Manresa F., Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004 Mar 8, 164:502-508.
20. Bodí M., Rodríguez A., Solé-Violán J., Gilavert M.C., Garnacho J., Blanquer J., et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005 Dec 15, 41(12):1709-1716.
21. Hosmer D., Lemeshow S. Applied logistic regression 1989, Wiley, New York.
22. Dupont M., Gacouin A., Lena H., Lavoué S., Brinchault G., Delaval P., et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest 2004 May, 125(5):1815-1820.
23. Alzeer A.H., Masood M., Basha S.J., Shaik S.A. Survival of bronchiectatic patients with respiratory failure in ICU. BMC Pulm Med 2007, 7:17.
24. Seitz A.E., Olivier K.N., Steiner C.A., Montes de O.R., Holland S.M., Prevots D.R. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010 Oct, 138(4):944-949.
25. Polverino E., Cillóniz C., Dambrava P., Gabarrús A., Ferrer M., Agustí C., et al. Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome. Respirology 2013 Feb, 18(2):263-271.
26. Malo de Molina R., Mortensen E.M., Restrepo M.I., Copeland L.A., Pugh M.J., Anzueto A. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010 Oct, 36(4):751-757.
27. Chen D., Restrepo M.I., Fine M.J., Pugh M.J., Anzueto A., Metersky M.L., et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011 Aug 1, 184(3):312-316.
28. Ferrer M., Torres A., Martínez R., Ramírez P., Polverino E., Montull B. Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study. Respirology 2014 Aug, 19(6):929-935.
29. Sellares J., López-Giraldo A., Lucena C., Cilloniz C., Amaro R., Polverino E., et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013 Jun 1, 187(11):1241-1248.
30. Krüger S., Ewig S., Kunde J., Hartmann O., Marre R., Suttorp N., et al. Assessment of inflammatory markers in patients with community-acquired pneumonia-influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta 2010 Dec 14, 411(23-24):1929-1934.
31. Ruiz M., Ewig S., Torres A., Arancibia F., Marco F., Mensa J., et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999 Sep, 160:923-929.
32. Schaaf B., Kruse J., Rupp J., Reinert R.R., Droemann D., Zabel P., et al. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J 2007 Sep, 30(3):517-524.
33. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. 15 A.D.
34. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001 Jun, 163:1730-1754.
35. McDonnell M.J., Jary H.R., Perry A., MacFarlane J.G., Hester K.L., Small T., et al. Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med 2014 Aug 29, pii: S0954-6111(14)00284-4. [Epub ahead of print]. 10.1016/j.rmed.2014.07.021.
36. Arancibia F., Bauer T.T., Ewig S., Mensa J., Gonzalez J., Niederman M.S., et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002 Sep 9, 162(16):1849-1858.
37. Polverino E., Dambrava P., Cillóniz C., Balasso V., Marcos M.A., Esquinas C., et al. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax 2010 Apr, 65(4):354-359.